Base de dados : MEDLINE
Pesquisa : C12.777.934 [Categoria DeCS]
Referências encontradas : 9108 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 911 ir para página                         

  1 / 9108 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29215339
[Au] Autor:Uçar M; Karagözlü Akgül A; Kiliç N; Balkan E
[Ad] Endereço:Department of Pediatric Surgery, Division of Pediatric Urology, Uludag University School of Medicine, Bursa, Turkey.
[Ti] Título:The Association of Congenital Urethral Duplication and Double Megalourethra.
[So] Source:Balkan Med J;34(6):572-575, 2017 12 01.
[Is] ISSN:2146-3131
[Cp] País de publicação:Turkey
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Urethral duplication and megalourethra are rare urethral anomalies. However, the concomitance of urethral duplication and double megalourethra has not been reported previously. CASE REPORT: A newborn was presented with penile swelling during voiding. Physical examination revealed a retractable foreskin and two external meatus of a double urethra. Retrograde urethrography demonstrated two complete megalourethras. Urethro-urethrostomy and urethroplasty were performed when the patient was 10 months old. The patient was followed up for one year without any urinary problems and has good cosmetics and urinary continence. CONCLUSION: The concomitance of these two rare anomalies and more importantly its surgical treatment makes this case report unique and valuable.
[Mh] Termos MeSH primário: Uretra/anormalidades
Uretra/cirurgia
Doenças Uretrais/cirurgia
Transtornos Urinários/cirurgia
Procedimentos Cirúrgicos Urológicos
[Mh] Termos MeSH secundário: Anormalidades Múltiplas/diagnóstico por imagem
Anormalidades Múltiplas/fisiopatologia
Anormalidades Múltiplas/cirurgia
Seguimentos
Seres Humanos
Recém-Nascido
Masculino
Doenças Raras
Resultado do Tratamento
Uretra/diagnóstico por imagem
Uretra/fisiopatologia
Doenças Uretrais/diagnóstico por imagem
Doenças Uretrais/fisiopatologia
Transtornos Urinários/diagnóstico por imagem
Transtornos Urinários/fisiopatologia
Urografia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.4274/balkanmedj.2017.0471


  2 / 9108 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463151
[Au] Autor:O'Callaghan ME; Raymond E; Campbell JM; Vincent AD; Beckmann K; Roder D; Evans S; McNeil J; Millar J; Zalcberg J; Borg M; Moretti K
[Ad] Endereço:South Australian Prostate Cancer Clinical Outcomes Collaborative; Freemasons Foundation Centre for Men's Health, University of Adelaide; Urology Unit, Repatriation General Hospital, SA Health; Flinders Centre for Innovation in Cancer. Electronic address: elspeth.raymond@health.sa.gov.au.
[Ti] Título:Patient-Reported Outcomes After Radiation Therapy in Men With Prostate Cancer: A Systematic Review of Prognostic Tool Accuracy and Validity.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):318-337, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To identify, through a systematic review, all validated tools used for the prediction of patient-reported outcome measures (PROMs) in patients being treated with radiation therapy for prostate cancer, and provide a comparative summary of accuracy and generalizability. METHODS AND MATERIALS: PubMed and EMBASE were searched from July 2007. Title/abstract screening, full text review, and critical appraisal were undertaken by 2 reviewers, whereas data extraction was performed by a single reviewer. Eligible articles had to provide a summary measure of accuracy and undertake internal or external validation. Tools were recommended for clinical implementation if they had been externally validated and found to have accuracy ≥70%. RESULTS: The search strategy identified 3839 potential studies, of which 236 progressed to full text review and 22 were included. From these studies, 50 tools predicted gastrointestinal/rectal symptoms, 29 tools predicted genitourinary symptoms, 4 tools predicted erectile dysfunction, and no tools predicted quality of life. For patients treated with external beam radiation therapy, 3 tools could be recommended for the prediction of rectal toxicity, gastrointestinal toxicity, and erectile dysfunction. For patients treated with brachytherapy, 2 tools could be recommended for the prediction of urinary retention and erectile dysfunction. CONCLUSIONS: A large number of tools for the prediction of PROMs in prostate cancer patients treated with radiation therapy have been developed. Only a small minority are accurate and have been shown to be generalizable through external validation. This review provides an accessible catalogue of tools that are ready for clinical implementation as well as which should be prioritized for validation.
[Mh] Termos MeSH primário: Disfunção Erétil/etiologia
Gastroenteropatias/etiologia
Medidas de Resultados Relatados pelo Paciente
Neoplasias da Próstata/radioterapia
Retenção Urinária/etiologia
[Mh] Termos MeSH secundário: Idoso
Braquiterapia/efeitos adversos
Coleta de Dados/métodos
Seres Humanos
Masculino
Prognóstico
Estudos Prospectivos
Neoplasias da Próstata/patologia
Qualidade de Vida
Reprodutibilidade dos Testes
Estudos Retrospectivos
Transtornos Urinários/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  3 / 9108 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29211750
[Au] Autor:Warden CH; Bettaieb A; Min E; Fisler JS; Haj FG; Stern JS
[Ad] Endereço:Departments of Pediatrics, Neurobiology Physiology and Behavior, University of California, Davis, Davis, CA, United States of America.
[Ti] Título:Chow fed UC Davis strain female Lepr fatty Zucker rats exhibit mild glucose intolerance, hypertriglyceridemia, and increased urine volume, all reduced by a Brown Norway strain chromosome 1 congenic donor region.
[So] Source:PLoS One;12(12):e0188175, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Our objective is to identify genes that influence the development of any phenotypes of type 2 diabetes (T2D) or kidney disease in obese animals. We use the reproductively isolated UC Davis fatty Zucker strain rat model in which the defective chromosome 4 leptin receptor (LeprfaSte/faSte) results in fatty obesity. We previously produced a congenic strain with the distal half of chromosome 1 from the Brown Norway strain (BN) on a Zucker (ZUC) background (BN.ZUC-D1Rat183-D1Rat90). Previously published studies in males showed that the BN congenic donor region protects from some phenotypes of renal dysfunction and T2D. We now expand our studies to include females and expand phenotyping to gene expression. We performed diabetes and kidney disease phenotyping in chow-fed females of the BN.ZUC-D1Rat183-D1Rat90 congenic strain to determine the specific characteristics of the UC Davis model. Fatty LeprfaSte/faSte animals of both BN and ZUC genotype in the congenic donor region had prediabetic levels of fasting blood glucose and blood glucose 2 hours after a glucose tolerance test. We observed significant congenic strain chromosome 1 genotype effects of the BN donor region in fatty females that resulted in decreased food intake, urine volume, glucose area under the curve during glucose tolerance test, plasma triglyceride levels, and urine glucose excretion per day. In fatty females, there were significant congenic strain BN genotype effects on non-fasted plasma urea nitrogen, triglyceride, and creatinine. Congenic region genotype effects were observed by quantitative PCR of mRNA from the kidney for six genes, all located in the chromosome 1 BN donor region, with potential effects on T2D or kidney function. The results are consistent with the hypothesis that the BN genotype chromosome 1 congenic region influences traits of both type 2 diabetes and kidney function in fatty UC Davis ZUC females and that there are many positional candidate genes.
[Mh] Termos MeSH primário: Ração Animal
Cromossomos de Mamíferos
Teste de Tolerância a Glucose
Transtornos Urinários/genética
[Mh] Termos MeSH secundário: Animais
Diabetes Mellitus Experimental/genética
Comportamento Alimentar
Feminino
Testes de Função Renal
Ratos
Ratos Zucker
Reação em Cadeia da Polimerase em Tempo Real
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171229
[Lr] Data última revisão:
171229
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171207
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0188175


  4 / 9108 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29197314
[Au] Autor:Meekins AR; Siddiqui NY; Amundsen CL; Kuchibhatla M; Dieter AA
[Ad] Endereço:From the Departments of Obstetrics and Gynecology and Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina, and the Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill.
[Ti] Título:Improving Postoperative Efficiency: An Algorithm for Expedited Void Trials After Urogynecologic Surgery.
[So] Source:South Med J;110(12):785-790, 2017 Dec.
[Is] ISSN:1541-8243
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To evaluate the relation between voided volume and void trial "success" to create an algorithm that minimizes the need for postvoid residual volume (PVR) assessment in backfill-assisted void trials. METHODS: This article is an ancillary analysis of deidentified data from a randomized trial evaluating prophylactic antibiotics after urogynecologic surgery. Void trials were routinely performed after surgery; voided volumes, PVR, and void trial outcomes were collected. The void trial regimen was as follows: the bladder was backfilled with 300 mL of normal saline or until the patient reported the urgency to void, the catheter was removed, and the participant was prompted to void immediately. PVR volume was measured either by sonographic bladder scan or catheterization. Voided volumes were categorized in 25-mL increments from 50 to 225 mL. For each voided volume range, the PVR and void trial outcome data were incorporated to calculate sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) in terms of ability of voided volume alone to predict a passing void trial result. An algorithm was created using the voided volumes that optimize PPV and NPV. RESULTS: The study population included 255 participants. Voided volumes <100 mL and ≥200 mL were identified as optimal thresholds to predict failure and passage of backfill-assisted void trials, respectively. When patients voided <100 mL, 3% passed their void trial (NPV odds ratio 96.7, 95% confidence interval 88.6-99.5). When patients voided ≥200 mL, 97% passed (PPV odds ratio 97.4, 95% confidence interval 93.5-99.3). CONCLUSIONS: We propose an algorithm for void trials after urogynecologic surgery. After backfilling the bladder if voided volume is ≥200 mL, the void trial is successful and no PVR is needed; if voided volume is between 100 and 199 mL, the void trial is indeterminate and PVR is recommended; and if voided volume is <100 mL, the void trial is unsuccessful and catheterization is needed. Applying this algorithm to our study population would have eliminated the need for PVR in 85% of patients. Calculated PPVs and NPVs depend on the prevalence of voiding dysfunction in the population being studied, and therefore may be unique to our institution.
[Mh] Termos MeSH primário: Procedimentos Cirúrgicos em Ginecologia/efeitos adversos
Pelve/cirurgia
Cuidados Pós-Operatórios/métodos
Complicações Pós-Operatórias/diagnóstico
Transtornos Urinários/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Idoso
Algoritmos
Feminino
Seres Humanos
Meia-Idade
Complicações Pós-Operatórias/etiologia
Valor Preditivo dos Testes
Estudos Retrospectivos
Sensibilidade e Especificidade
Fatores de Tempo
Bexiga Urinária/fisiopatologia
Micção/fisiologia
Transtornos Urinários/etiologia
Urodinâmica
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171220
[Lr] Data última revisão:
171220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171203
[St] Status:MEDLINE
[do] DOI:10.14423/SMJ.0000000000000733


  5 / 9108 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28834453
[Au] Autor:Shore ND; Boorjian SA; Canter DJ; Ogan K; Karsh LI; Downs TM; Gomella LG; Kamat AM; Lotan Y; Svatek RS; Bivalacqua TJ; Grubb RL; Krupski TL; Lerner SP; Woods ME; Inman BA; Milowsky MI; Boyd A; Treasure FP; Gregory G; Sawutz DG; Yla-Herttuala S; Parker NR; Dinney CPN
[Ad] Endereço:Neal D. Shore, Carolina Urologic Research Center, Myrtle Beach, SC; Stephen A. Boorjian, Mayo Clinic, Rochester, MN; Daniel J. Canter, Ochsner Health System, New Orleans, LA; Kenneth Ogan, Emory University, Atlanta, GA; Lawrence I. Karsh, The Urology Center of Colorado, Denver, CO; Tracy M. Downs, U
[Ti] Título:Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.
[So] Source:J Clin Oncol;35(30):3410-3416, 2017 Oct 20.
[Is] ISSN:1527-7755
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose Many patients with high-risk non-muscle-invasive bladder cancer (NMIBC) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse. We assessed the efficacy and safety of recombinant adenovirus interferon alfa with Syn3 (rAd-IFNα/Syn3), a replication-deficient recombinant adenovirus gene transfer vector, for patients with high-grade (HG) BCG-refractory or relapsed NMIBC. Methods In this open-label, multicenter (n = 13), parallel-arm, phase II study ( ClinicalTrials.gov identifier: NCT01687244), 43 patients with HG BCG-refractory or relapsed NMIBC received intravesical rAd-IFNα/Syn3 (randomly assigned 1:1 to 1 × 10 viral particles (vp)/mL or 3 × 10 vp/mL). Patients who responded at months 3, 6, and 9 were retreated at months 4, 7, and 10. The primary end point was 12-month HG recurrence-free survival (RFS). All patients who received at least one dose were included in efficacy and safety analyses. Results Forty patients received rAd-IFNα/Syn3 (1 × 10 vp/mL, n = 21; 3 × 10 vp/mL, n = 19) between November 5, 2012, and April 8, 2015. Fourteen patients (35.0%; 90% CI, 22.6% to 49.2%) remained free of HG recurrence 12 months after initial treatment. Comparable 12-month HG RFS was noted for both doses. Of these 14 patients, two experienced recurrence at 21 and 28 months, respectively, after treatment initiation, and one died as a result of an upper tract tumor at 17 months without a recurrence. rAd-IFNα/Syn3 was well tolerated; no grade four or five adverse events (AEs) occurred, and no patient discontinued treatment because of an adverse event. The most frequently reported drug-related AEs were micturition urgency (n = 16; 40%), dysuria (n = 16; 40%), fatigue (n = 13; 32.5%), pollakiuria (n = 11; 28%), and hematuria and nocturia (n = 10 each; 25%). Conclusion rAd-IFNα/Syn3 was well tolerated. It demonstrated promising efficacy for patients with HG NMIBC after BCG therapy who were unable or unwilling to undergo radical cystectomy.
[Mh] Termos MeSH primário: Terapia Genética/métodos
Interferon-alfa/metabolismo
Neoplasias da Bexiga Urinária/terapia
[Mh] Termos MeSH secundário: Adenoviridae/genética
Administração Intravesical
Idoso
Idoso de 80 Anos ou mais
Vacina BCG/administração & dosagem
Ácidos Cólicos/química
Dissacarídeos/química
Resistência a Medicamentos Antineoplásicos
Fadiga/etiologia
Feminino
Terapia Genética/efeitos adversos
Vetores Genéticos/administração & dosagem
Vetores Genéticos/genética
Seres Humanos
Interferon-alfa/química
Interferon-alfa/genética
Masculino
Meia-Idade
Gradação de Tumores
Invasividade Neoplásica
Recidiva Local de Neoplasia
Proteínas Recombinantes de Fusão/química
Proteínas Recombinantes de Fusão/genética
Proteínas Recombinantes de Fusão/metabolismo
Proteínas Recombinantes/química
Proteínas Recombinantes/genética
Proteínas Recombinantes/metabolismo
Resultado do Tratamento
Neoplasias da Bexiga Urinária/genética
Neoplasias da Bexiga Urinária/patologia
Transtornos Urinários/etiologia
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (BCG Vaccine); 0 (Cholic Acids); 0 (Disaccharides); 0 (Interferon-alpha); 0 (Recombinant Fusion Proteins); 0 (Recombinant Proteins); 0 (Syn3 compound); 43K1W2T1M6 (interferon alfa-2b)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170824
[St] Status:MEDLINE
[do] DOI:10.1200/JCO.2017.72.3064


  6 / 9108 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28586948
[Au] Autor:Hafeez S; McDonald F; Lalondrelle S; McNair H; Warren-Oseni K; Jones K; Harris V; Taylor H; Khoo V; Thomas K; Hansen V; Dearnaley D; Horwich A; Huddart R
[Ad] Endereço:The Institute of Cancer Research, London; The Royal Marsden NHS Foundation Trust, Sutton, Surrey. Electronic address: shaista.hafeez@icr.ac.uk.
[Ti] Título:Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment.
[So] Source:Int J Radiat Oncol Biol Phys;98(1):115-122, 2017 May 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE AND OBJECTIVES: We report on the clinical outcomes of a phase 2 study assessing image guided hypofractionated weekly radiation therapy in bladder cancer patients unsuitable for radical treatment. METHODS AND MATERIALS: Fifty-five patients with T2-T4aNx-2M0-1 bladder cancer not suitable for cystectomy or daily radiation therapy treatment were recruited. A "plan of the day" radiation therapy approach was used, treating the whole (empty) bladder to 36 Gy in 6 weekly fractions. Acute toxicity was assessed weekly during radiation therapy, at 6 and 12 weeks using the Common Terminology Criteria for Adverse Events version 3.0. Late toxicity was assessed at 6 months and 12 months using Radiation Therapy Oncology Group grading. Cystoscopy was used to assess local control at 3 months. Cumulative incidence function was used to determine local progression at 1 at 2 years. Death without local progression was treated as a competing risk. Overall survival was estimated using the Kaplan-Meier method. RESULTS: Median age was 86 years (range, 68-97 years). Eighty-seven percent of patients completed their prescribed course of radiation therapy. Genitourinary and gastrointestinal grade 3 acute toxicity was seen in 18% (10/55) and 4% (2/55) of patients, respectively. No grade 4 genitourinary or gastrointestinal toxicity was seen. Grade ≥3 late toxicity (any) at 6 and 12 months was seen in 6.5% (2/31) and 4.3% (1/23) of patients, respectively. Local control after radiation therapy was 92% of assessed patients (60% total population). Cumulative incidence of local progression at 1 year and 2 years for all patients was 7% (95% confidence interval [CI] 2%-17%) and 17% (95% CI 8%-29%), respectively. Overall survival at 1 year was 63% (95% CI 48%-74%). CONCLUSION: Hypofractionated radiation therapy delivered weekly with a plan of the day approach offers good local control with acceptable toxicity in a patient population not suitable for radical bladder treatment.
[Mh] Termos MeSH primário: Radioterapia Hipofracionada
Radioterapia Guiada por Imagem/métodos
Neoplasias da Bexiga Urinária/radioterapia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Carcinoma de Células Escamosas/mortalidade
Carcinoma de Células Escamosas/patologia
Carcinoma de Células Escamosas/radioterapia
Carcinoma de Células de Transição/mortalidade
Carcinoma de Células de Transição/patologia
Carcinoma de Células de Transição/radioterapia
Cistectomia
Progressão da Doença
Feminino
Gastroenteropatias/etiologia
Seres Humanos
Estimativa de Kaplan-Meier
Masculino
Estudos Prospectivos
Lesões por Radiação/patologia
Planejamento da Radioterapia Assistida por Computador
Radioterapia Guiada por Imagem/efeitos adversos
Fatores de Tempo
Resultado do Tratamento
Bexiga Urinária/efeitos da radiação
Neoplasias da Bexiga Urinária/mortalidade
Neoplasias da Bexiga Urinária/patologia
Transtornos Urinários/etiologia
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170721
[Lr] Data última revisão:
170721
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170608
[St] Status:MEDLINE


  7 / 9108 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28581398
[Au] Autor:Rodda S; Morris WJ; Hamm J; Duncan G
[Ad] Endereço:BC Cancer Agency, Vancouver Centre, Vancouver, British Columbia, Canada.
[Ti] Título:ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
[So] Source:Int J Radiat Oncol Biol Phys;98(3):581-589, 2017 Jul 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To report the patient-reported health-related quality of life (HR-QoL) outcomes for a multicenter randomized trial evaluating the safety and efficacy of 2 different techniques for dose escalation. METHODS AND MATERIALS: A total of 357 men with intermediate- and high-risk prostate cancer were stratified by risk group and randomized (1:1) to either a dose-escalated external beam (DE-EBRT) boost (n=177) or a low-dose-rate prostate brachytherapy (LDR-PB) boost (n=180) as part of combined modality therapy. The HR-QoL was assessed using the SF36v2 questionnaire, with additional scales for urinary, bowel, and sexual function. Date of starting androgen deprivation therapy was considered time zero, the median follow-up of 6 years. Scales were scored from 0 to 100; a decline in a mean score ≥10 compared with baseline was considered a clinically significant decline. This was an intent-to-treat analysis. RESULTS: Mean domain scores at baseline were well balanced between the 2 treatment arms. A clinically significant decline in mean scores in both the arms compared with baseline was noted for role physical (DE-EBRT [-11.4] and LDR-PB [-15.3]) and sexual function scale (DE-EBRT [-15.1] and LDR-PB [-19.2]). There was a significantly larger drop in mean scores in the LDR-PB group compared with the DE-EBRT group for physical function (-15.3 vs -6.9; P=.03), urinary function (-3.6 vs -0.5; P=.04). CONCLUSION: At 6 years' follow up, there were no significant differences in mean scores in 9 of 11 scales compared with baseline in both arms. A clinically significant decline in mean scores was noted in both arms for role physical and sexual function scales. There was a statistically significant decline in physical function and urinary function scales in the LDR-PB arm compared with the DE-EBRT arm.
[Mh] Termos MeSH primário: Braquiterapia/métodos
Neoplasias da Próstata/radioterapia
Qualidade de Vida
Reirradiação/métodos
[Mh] Termos MeSH secundário: Atividades Cotidianas
Idoso
Idoso de 80 Anos ou mais
Antagonistas de Androgênios/uso terapêutico
Antineoplásicos Hormonais/uso terapêutico
Estudos de Viabilidade
Flutamida/administração & dosagem
Hormônio Liberador de Gonadotropina/agonistas
Seres Humanos
Análise de Intenção de Tratamento
Masculino
Meia-Idade
Neoplasias da Próstata/tratamento farmacológico
Risco
Comportamento Sexual
Inquéritos e Questionários
Fatores de Tempo
Transtornos Urinários/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Androgen Antagonists); 0 (Antineoplastic Agents, Hormonal); 33515-09-2 (Gonadotropin-Releasing Hormone); 76W6J0943E (Flutamide)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170726
[Lr] Data última revisão:
170726
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170606
[St] Status:MEDLINE


  8 / 9108 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Antunes, Edson
Texto completo
[PMID]:28487215
[Au] Autor:Bonilla-Becerra SM; de Oliveira MG; Calmasini FB; Rojas-Moscoso JA; Zanesco A; Antunes E
[Ad] Endereço:Department of Pharmacology, Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
[Ti] Título:Micturition dysfunction in four-month old ovariectomized rats: Effects of testosterone replacement.
[So] Source:Life Sci;179:120-129, 2017 Jun 15.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:AIMS: Androgen deficiency has been implicated in urological complications of postmenopausal women. This study examined the effects of testosterone replacements on the lower urinary tract dysfunction in 4-month old ovariectomized (OVX) rats. MAIN METHODS: Sprague-Dawley female rats were OVX bilaterally. Three months later, rats received single intramuscular injections of testosterone undecanoate. Cystometric study, and bladder and urethra smooth muscle reactivities were evaluated. KEY FINDINGS: Ovariectomy reduced by 65% (p<0.05) the serum testosterone levels. Testosterone replacement at 5mg/kg restored serum hormone levels to baseline, whereas 10mg/kg produced 14-fold higher testosterone levels. OVX rats exhibited significant increases of body weight, perigonadal fat and blood pressure, and reduced uterus weight, but none of these parameters were changed by testosterone replacements. OVX rats exhibited micturition dysfunction characterized by increases of basal pressure, threshold pressure, voiding frequency and post-voiding pressure. In addition, the bladder contractions induced by electrical-field stimulation (EFS) and carbachol were significantly reduced, whereas angiotensin II-induced urethral contractions were significantly increased in OVX rats. Testosterone replacement at 10mg/kg (but not at 5mg/kg) dose fully normalized the in vivo micturition dysfunction, as well as the in vitro bladder and urethral alterations. Testosterone (10mg/kg) also significantly potentiated the bladder relaxations induced by the ß -adrenoceptor agonist mirabegron. The protective effects of testosterone were not modified by concomitant treatment with the aromatase inhibitor letrozole (2.5mg/kg, 4weeks). SIGNIFICANCE: The improvement of micturition dysfunction by testosterone replacement suggests that androgen therapy might be of therapeutic benefit for urological complications associated with post-menopause.
[Mh] Termos MeSH primário: Androgênios/administração & dosagem
Músculo Liso/efeitos dos fármacos
Pós-Menopausa
Testosterona/análogos & derivados
Transtornos Urinários/tratamento farmacológico
[Mh] Termos MeSH secundário: Acetanilidas/farmacologia
Androgênios/farmacologia
Angiotensina II/farmacologia
Animais
Carbacol/farmacologia
Modelos Animais de Doenças
Relação Dose-Resposta a Droga
Feminino
Injeções Intramusculares
Músculo Liso/metabolismo
Nitrilos/farmacologia
Ovariectomia
Ratos
Ratos Sprague-Dawley
Testosterona/administração & dosagem
Testosterona/farmacologia
Tiazóis/farmacologia
Triazóis/farmacologia
Uretra/efeitos dos fármacos
Uretra/metabolismo
Transtornos Urinários/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acetanilides); 0 (Androgens); 0 (Nitriles); 0 (Thiazoles); 0 (Triazoles); 11128-99-7 (Angiotensin II); 3XMK78S47O (Testosterone); 7LKK855W8I (letrozole); 8Y164V895Y (Carbachol); H16A5VCT9C (testosterone undecanoate); MVR3JL3B2V (mirabegron)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170629
[Lr] Data última revisão:
170629
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170511
[St] Status:MEDLINE


  9 / 9108 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28444713
[Au] Autor:Gajewski JB; Rosier PFWM; Rahnama'i S; Abrams P
[Ad] Endereço:Department of Urology, Dalhousie University, Halifax, Canada.
[Ti] Título:Do we assess urethral function adequately in LUTD and NLUTD? ICI-RS 2015.
[So] Source:Neurourol Urodyn;36(4):935-942, 2017 04.
[Is] ISSN:1520-6777
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Urethral function, as well as anatomy, play a significant role in voiding reflex and abnormalities in one or both contribute to the pathophysiology of Lower Urinary Tract Dysfunction (LUTD). We have several diagnostic tools to assess the urethral function or dysfunction but the question remains, are these adequate? METHODS: This is a report of the proceedings of Think Tank P1: 'Do we assess urethral function adequately in LUTD and NLUTD?' from the annual International Consultation on Incontinence-Research Society, which took place September 22-24, 2014 in Bristol, UK. RESULTS: We have collected and discussed, as a committee, the evidence with regard to the urethra and the available relevant methods of testing urethral function, with the emphasis on female and male voiding dysfunction. We looked into previous research and clinical studies and compiled summaries of pertinent testing related to urethral function. The discussion has focused on clinical applications and the desirability of further development of functional tests and analyses in this field. CONCLUSIONS: There are limitations to most of the urethral function tests. Future perspectives and research should concentrate on further development of functional testing and imaging techniques with emphasis on standardization and clinical application of these tests. Neurourol. Urodynam. 36:935-942, 2017. © 2017 Wiley Periodicals, Inc.
[Mh] Termos MeSH primário: Sintomas do Trato Urinário Inferior/fisiopatologia
Uretra/fisiopatologia
[Mh] Termos MeSH secundário: Estudos Clínicos como Assunto
Seres Humanos
Uretra/anatomia & histologia
Uretra/diagnóstico por imagem
Uretra/fisiologia
Transtornos Urinários/diagnóstico por imagem
Transtornos Urinários/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171121
[Lr] Data última revisão:
171121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170427
[St] Status:MEDLINE
[do] DOI:10.1002/nau.23100


  10 / 9108 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28433432
[Au] Autor:Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
[Ad] Endereço:British Columbia (BC) Cancer Agency, Vancouver Centre, Vancouver, British Columbia, Canada.
[Ti] Título:ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):286-295, 2017 Jun 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To report the genitourinary (GU) and gastrointestinal (GI) morbidity and erectile dysfunction in a randomized trial comparing 2 methods of dose escalation for high- and intermediate-risk prostate cancer. METHODS AND MATERIALS: ASCENDE-RT (Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy) enrolled 398 men, median age 68 years, who were then randomized to either a standard arm that included 12 months of androgen deprivation therapy and pelvic irradiation to 46 Gy followed by a dose-escalated external beam radiation therapy (DE-EBRT) boost to 78 Gy, or an experimental arm that substituted a low-dose-rate prostate brachytherapy (LDR-PB) boost. At clinic visits, investigators recorded GU and GI morbidity and information on urinary continence, catheter use, and erectile function. Exclusion of 15 who received nonprotocol treatment and correction of 14 crossover events left 195 men who actually received a DE-EBRT boost and 188, an LDR-PB boost. Median follow-up was 6.5 years. RESULTS: The LDR-PB boost increased the risk of needing temporary catheterization and/or requiring incontinence pads. At 5 years the cumulative incidence of grade 3 GU events was 18.4% for LDR-PB, versus 5.2% for DE-EBRT (P<.001). Compared with the cumulative incidence, the 5-year prevalence of grade 3 GU morbidity was substantially lower for both arms (8.6% vs 2.2%, P=.058). The 5-year cumulative incidence of grade 3 GI events was 8.1% for LDR-PB, versus 3.2% for DE-EBRT (P=.124). The 5-year prevalence of grade 3 GI toxicity was lower than the cumulative incidence for both arms (1.0% vs 2.2%, respectively). Among men reporting adequate baseline erections, 45% of LDR-PB patients reported similar erectile function at 5 years, versus 37% after DE-EBRT (P=.30). CONCLUSIONS: The incidence of acute and late GU morbidity was higher after LDR-PB boost, and there was a nonsignificant trend for worse GI morbidity. No differences in the frequency of erectile dysfunction were observed.
[Mh] Termos MeSH primário: Braquiterapia/efeitos adversos
Disfunção Erétil/etiologia
Incontinência Fecal/etiologia
Neoplasias da Próstata/tratamento farmacológico
Neoplasias da Próstata/radioterapia
Radioterapia Conformacional/efeitos adversos
Transtornos Urinários/etiologia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Antagonistas de Androgênios/efeitos adversos
Antagonistas de Androgênios/uso terapêutico
Braquiterapia/métodos
Terapia Combinada/efeitos adversos
Terapia Combinada/métodos
Diarreia/epidemiologia
Diarreia/etiologia
Intervalo Livre de Doença
Disfunção Erétil/epidemiologia
Estudos de Viabilidade
Incontinência Fecal/epidemiologia
Seguimentos
Hemorragia Gastrointestinal/epidemiologia
Hemorragia Gastrointestinal/etiologia
Hormônio Liberador de Gonadotropina/efeitos adversos
Hormônio Liberador de Gonadotropina/uso terapêutico
Seres Humanos
Incidência
Análise de Intenção de Tratamento
Modelos Logísticos
Masculino
Meia-Idade
Pelve
Dosagem Radioterapêutica
Reirradiação/efeitos adversos
Reirradiação/métodos
Reto/efeitos da radiação
Fatores de Tempo
Incontinência Urinária/epidemiologia
Incontinência Urinária/etiologia
Transtornos Urinários/epidemiologia
Sistema Urogenital/efeitos da radiação
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Androgen Antagonists); 33515-09-2 (Gonadotropin-Releasing Hormone)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170726
[Lr] Data última revisão:
170726
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170424
[St] Status:MEDLINE



página 1 de 911 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde